https://www.tctmd.com/news/early-redo-tavi-outcomes-look-good-far-definitive
The above article examines whether TAV in TAV is a good option for patients going forward.
"long-term patient management is now at the forefront of physicians’ minds when they treat patients with severe symptomatic aortic stenosis"
"there is a growing awareness that younger, lower-risk patients with longer life expectancies will live beyond the valve’s life span, making TAV-in-TAV procedures more common going forward"
For AVR holders, the obvious point to make is the best option for patients would be if they did not need to replace it in the first place![]()
Good luck all.
- Forums
- ASX - By Stock
- Anteris Channel 9 Interview 2022
AVR
anteris technologies global corp.
Add to My Watchlist
3.43%
!
$5.91

https://www.tctmd.com/news/early-redo-tavi-outcomes-look-good-far...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.91 |
Change
-0.210(3.43%) |
Mkt cap ! $91.59M |
Open | High | Low | Value | Volume |
$6.01 | $6.08 | $5.85 | $44.71K | 7.43K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 857 | $5.83 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.08 | 260 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 857 | 5.830 |
1 | 900 | 5.780 |
1 | 1000 | 5.610 |
2 | 3500 | 5.600 |
2 | 3736 | 5.500 |
Price($) | Vol. | No. |
---|---|---|
6.080 | 260 | 1 |
6.180 | 50 | 1 |
6.200 | 1000 | 1 |
6.400 | 130 | 1 |
6.500 | 255 | 1 |
Last trade - 15.51pm 26/06/2025 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online